COVID-19 Therapeutics Market Research Report with Forecast 2026 to 2035
What is COVID-19 Therapeutics Market?
Global COVID-19 Therapeutics Market is expected to grow at a 15.0% CAGR during the forecast period for 2026 to 2035.
COVID-19 Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Anti-viral, Monoclonal Antibodies, Kinase Inhibitors, Others (anti-inflammatory drugs, convalescent plasma, others)), By Region, And By Segment Forecasts, 2026 to 2035

COVID-19 Therapeutics Market Key Takeaways:
|
The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the expansion of the COVID-19 therapeutics market during the forecast period. According to the World Health Organization (WHO), globally, 175,847,347 confirmed cases of COVID-19, including 3,807,276 deaths, were reported to WHO as of 15 June 2021. Covid-19 cases are increasing day by day, and there is no officially approved drug for COVID-19. Many countries are facing a shortage of drugs likely to offer growth opportunities for pharmaceutical drug manufacturers. Leading market players are also developing innovative and efficient covid-19 drug therapies, resulting in overall market growth.
Major factors responsible for the growth of the COVID 19 therapeutic market are the fast adoption of advanced technologies, the growing number of corona patients, increasing healthcare expenditures, rising awareness about coronavirus, and increasing efforts by the pharmaceutical companies to develop covid-19 therapeutic drugs. For instance, Eli Lilly and Company is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 treatments at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. Furthermore, increasing research investments for the R&D of covid-19 therapeutic drugs is anticipated to drive market growth in the future. However, the high cost required to validate therapies, and long-term clinical trials limit the COVID-19 therapeutics market growth.
Market Segmetation
The COVID-19 therapeutics market can be segmented into Drug Class, and Region. By Drug Claas, the market can be divided into Corticosteroids (Dexamethasone, Hydrocortisone, Methylprednisolone, Others (Prednisone, Others)), Anti-viral (Remdesivir, Nirmatrelvir, Others (Ivermectin, Others)), Monoclonal Antibodies (Sotrovimab, Casirivimab plus imdevimab, Others (Bamlanivimab plus etesevimab, Tixagevimab plus, cilgavimab, others), Kinase Inhibitors (Baricitinib, Others (Tofacitinib, Others)),Others (anti-inflammatory drugs, convalescent plasma, others). Regionally, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the COVID-19 therapeutics market in the coming future.
Competitive Landscape
Some major key players in the COVID-19 Therapeutics Market:
- AstraZeneca plc,
- Celltrion Healthcare Co.,Ltd,
- Pfizer Inc.,
- Ridgeback Biotherapeutics,
- Merck & Co.,
- Veru Inc.,
- Gilead Sciences, Inc.,
- GSK plc,
- Shionogi & Company, Limited,
- NRx Pharmaceuticals, Inc.,
- Kintor Pharma-B,
- Regeneron Pharmaceuticals,
- CytoDyn,
- Atea Pharmaceuticals, Inc.,
- Amarin Corporation,
- APEIRON Biologics AG,
- Abivax SA,
- Alexion Pharmaceuticals,
- Bellerophon Therapeutics,
- Blade Therapeutics, Inc,
- Roivant Sciences,
- Synairgen,
- Sorrento Therapeutics,
- Fulcrum Therapeutics,
- Ono Pharmaceutical Co., Ltd.,
- Revive Therapeutics Ltd.,
- other prominent players
COVID-19 Therapeutics Market Report Scope :
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 15.0% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn,and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026 to 2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Drug Class |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | AstraZeneca plc, Celltrion Healthcare Co.,Ltd, Pfizer Inc., Ridgeback Biotherapeutics, Merck & Co., Veru Inc., Gilead Sciences, Inc., GSK plc, Shionogi & Company, Limited, NRx Pharmaceuticals, Inc., Kintor Pharma-B, Regeneron Pharmaceuticals, CytoDyn, Atea Pharmaceuticals, Inc., Amarin Corporation, APEIRON Biologics AG, Abivax SA, Alexion Pharmaceuticals, Bellerophon Therapeutics, Blade Therapeutics, Inc, Roivant Sciences, Synairgen, Sorrento Therapeutics, Fulcrum Therapeutics, Ono Pharmaceutical Co., Ltd., Revive Therapeutics Ltd., and other prominent players |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of COVID-19 Therapeutics Market :
COVID-19 therapeutics Market based on Drug Class-
- Corticosteroids
- Dexamethasone
- Hydrocortisone
- Methylprednisolone
- Others (Prednisone, Others)
- Anti-viral
- Remdesivir
- Nirmatrelvir
- Others (Ivermectin, Others)
- Monoclonal Antibodies
- Sotrovimab
- Casirivimab plus imdevimab
- Others (Bamlanivimab plus etesevimab, Tixagevimab plus, cilgavimab, others)
- Kinase Inhibitors
- Baricitinib
- Others (Tofacitinib, Others)
- Others (anti-inflammatory drugs, convalescent plasma, others)

COVID-19 therapeutics Market based on Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
AstraZeneca plc, Celltrion Healthcare Co.,Ltd, Pfizer Inc., Ridgeback Biotherapeutics, Merck & Co., Veru Inc., Gilead Sciences, Inc., GSK plc, Shionogi & Company, Limited, NRx Pharmaceuticals, Inc., Kintor Pharma-B, Regeneron Pharmaceuticals, CytoDyn, Atea Pharmaceuticals, Inc., Amarin Corporation, APEIRON Biologics AG, Abivax SA, Alexion Pharmaceuticals, Bellerophon Therapeutics, Blade Therapeutics, Inc, Roivant Sciences, Synairgen, Sorrento Therapeutics, Fulcrum Therapeutics, Ono Pharmaceutical Co., Ltd., Revive Therapeutics Ltd., and other prominent players
COVID-19 Therapeutics Market is expected to grow at a 15.0 % CAGR during the forecast period for 2026 to 2035
Drug Class are the key segments of the COVID-19 Therapeutics Market.
North America region is leading the COVID-19 Therapeutics Market.
